About 1.3 billion people around the world were living with Metabolic dysfunction-associated steatotic liver disease (MASLD) in 2023, marking a 143 per cent increase since 1990, a study published in The Lancet Gastroenterology and Hepatology journal has estimated.
The analysis, based on data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023, also projected that global cases of MASLD could rise to about 1.8 billion by 2050, driven largely by population growth and lifestyle changes, including increasing rates of obesity and high blood sugar.
Researchers forming the GBD 2023 MASLD Collaborators also found that regions such as North Africa and the Middle East had disproportionately higher rates of MASLD than other regions.
They also found that although more people are developing the disease, the overall impact on health — measured in years lost due to illness or death — has remained stable.
The result suggested that advances in treatment and care are help​About 1.3 billion people around the world were living with Metabolic dysfunction-associated steatotic liver disease (MASLD) in 2023, marking a 143 per cent increase since 1990, a study published in The Lancet Gastroenterology and Hepatology journal has estimated.
The analysis, based on data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023, also projected that global cases of MASLD could rise to about 1.8 billion by 2050, driven largely by population growth and lifestyle changes, including increasing rates of obesity and high blood sugar.
Researchers forming the GBD 2023 MASLD Collaborators also found that regions such as North Africa and the Middle East had disproportionately higher rates of MASLD than other regions.
They also found that although more people are developing the disease, the overall impact on health — measured in years lost due to illness or death — has remained stable.
The result suggested that advances in treatment and care are help ​Latest News [ SOBAN NEWS: International and National ]
